Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study

Medicine (United States)

Volumn 95, Issue 27, 2016, Pages

  Ko, Seung Hyun ^a   Kim, Dae Jung ^b   Park, Jong Heon ^c   Park, Cheol Young ^c   Jung, Chang Hee ^d   Kwon, Hyuk Sang ^a   Park, Joong Yeol ^d   Song, Kee Ho ^e   Han, Kyungdo ^a   Lee, Ki Up ^d   Ko, Kyung Soo ^f  

^a The Catholic University of Korea   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Konkuk University School of Medicine   (South Korea)

^f Inje University College of Medicine   (South Korea)

Author keywords

Antidiabetic medication; Diabetes type 2; Dipeptidyl peptidase 4 inhibitor; Insulin; Metformin; National Health Insurance; Sulfonylurea

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG COST; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CLINICAL PRACTICE; DIABETES MELLITUS, TYPE 2; ECONOMICS; FEE; SOUTH KOREA; STATISTICS AND NUMERICAL DATA;

ADULT; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTION FEES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 84978708609     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004018     Document Type: Article

References (34)

1. Jeon JY, Ko SH, Kwon HS, et al. Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes AssociationPrevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J 2013;37:349-57
2. American Diabetes AssociationEconomic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
3. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-23
4. Statistics Korea 2013. Available from: http://kostat.go.kr/portal/korea/ index.action.(latest update 2015 Dec 7)
5. Jin DC. Major changes and improvements of dialysis therapy in Korea: review of end-stage renal disease registry. Korean J Intern Med 2015;30: 17-22
6. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
7. American Diabetes AssociationStandards of medical care in diabetes-2015. Diabetes Care 2015;38(Suppl 1):S41-48
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38: 140-9
9. Ko SH, Kim SR, Kim DJ, et al. Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011;35:431-6
10. International Diabetes Federation Guideline Development GroupGlobal guideline for type 2 diabetes. Diabetes Res Clin Pract 2014;104:1-52
11. Jeon JY, Kim DJ, Ko SH, et al. Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Current status of glycemic control of patients with diabetes in Korea: the fifth Korea national health and nutrition examination survey. Diabetes Metab J 2014;38:197-203
12. Song SO, Jung CH, Song YD, et al. Background and data configuration process of a nationwide population-based study using the Korean national health insurance system. Diabetes Metab J 2014;38:395-403
13. Koo BK, Lee CH, Yang BR, Hwang SS, Choi NK. The incidence and prevalence of diabetes mellitus and related atherosclerotic complications in Korea: a National Health Insurance Database Study. PLoS One 2014;9:e110650
14. Alexander GC, Sehgal NL, Moloney RM, Stafford RS.National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-94
15. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care 2014;37:985-92
16. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care 2014;37: 1367-74
17. Lee YH, Han K, Ko SH, Ko KS, Lee KU. Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Data Analytic Process of a Nationwide Population-Based Study Using National Health Information Database Established by National Health Insurance Service. Diabetes Metab J 2016;40:79-82
18. Skaer TL, Sclar DA, Robison LM, Markowski DJ, Won JK. Effect of pharmaceutical formulation for diltiazem on health care expenditures for hypertension. Clin Ther 1993;15:905-11
19. Garci'a-Pe'rez LE, Alvarez M, Dilla T,Gil-Guille'n V,Orozco-Beltra'n D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013;4:175-94
20. Wong HK, Ong KL, Cheung CL, Cheung BM. Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States. Ann Epidemiol 2014;24:516-21
21. UK., Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
22. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
23. Yoon KH, Shin JA, Kwon HS, et al. Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in Korean drugnaïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J 2011;35:26-33
24. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2014;16:410-7
25. Wainstein J, Katz L, Engel SS, Xu L, et al. Initial therapy with the fixeddose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2012;14:409-18
26. Blonde L, San Juan ZT, Bolton P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract 2014;20:1322-32
27. Herman WH. The economic costs of diabetes: is it time for a new treatment paradigm? Diabetes Care 2013;36:775-6
28. Ministry of Health, Labour and Welfare 2012. Reference data of Healthy Japan 21 (in Japanese). Available at: http://www.mhlw.go.jp/bunya/ kenkou/dl/kenkounippon21-02.pdf
29. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009;25:705-16
30. Huber CA, Schwenkglenks M, Rapold R, Reich O. Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011. BMC Endocr Disord 2014;14:44
31. Park IeB , Kim J, Kim DJ, et al. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association. Diabetes epidemics in Korea: reappraise nationwide survey of diabetes "diabetes in Korea 2007". Diabetes Metab J 2013;37:233-9
32. Shin DW, Park JH, Park JH, et al. Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study. Support Care Cancer 2011;19:211-20
33. Vervloet M, van Dijk L, Santen-Reestman J, van Vlijmen B, Bouvy ML, de Bakker DH. Improving medication adherence in diabetes type 2 patients through Real Time Medication Monitoring: a randomised controlled trial to evaluate the effect of monitoring patients' medication use combined with short message service (SMS) reminders. BMC Health Serv Res 2011;11:5
34. WHOAdherence to long-term therapies. Evidence for action. Geneva, World Health Organisation 2003